Assessing metabolomics and genetics for diagnosing pancreatic tumors in MEN1 patients
Metabolomics and Genetic Diagnosing Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1 Patients
This study is testing if looking at blood samples and genes can help doctors better diagnose pancreatic tumors in people with MEN1 and understand how these tumors behave.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 629 (estimated) |
| Sex | All |
| Sponsor | M.D. Anderson Cancer Center Academic / other |
| Locations | 1 site (Houston, Texas) |
| Trial ID | NCT03048266 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the role of metabolomics and genetics in diagnosing and assessing survival outcomes for pancreatic neuroendocrine tumors (PNET) in patients with Multiple Endocrine Neoplasia type 1 (MEN1). It will involve a nested case-control design comparing patients with aggressive PNETs to those with non-aggressive forms. The study will analyze serum metabolic profiles and validate potential miRNA biomarkers to improve diagnostic accuracy and patient management. The findings could enhance understanding of tumor behavior and patient prognosis.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with a confirmed diagnosis of MEN1 and no prior history of pancreatic neuroendocrine tumors.
Not a fit: Patients with a history of pancreatic neuroendocrine tumors prior to the study will not benefit from this research.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic methods and better survival outcomes for MEN1 patients with pancreatic neuroendocrine tumors.
How similar studies have performed: While the specific approach of combining metabolomics and genetics in this context may be novel, similar studies have shown promise in identifying biomarkers for various cancers.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. The study will include all patients with a confirmed MEN1 diagnosis (clinical, genetic or familial criteria). 2. No prior history of PNET. Exclusion Criteria: N/A
Where this trial is running
Houston, Texas
- University of Texas MD Anderson Cancer Center — Houston, Texas, United States (Recruiting)
Study contacts
- Principal investigator: Nancy D. Perrier, MD — M.D. Anderson Cancer Center
- Study coordinator: Nancy D. Perrier, MD
- Email: NPerrier@mdanderson.org
- Phone: 713-792-6940
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.